MYRIAD GENETICS INC
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | After market close | $190.70M | $-0.46 | $-0.25 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $200.40M | $-0.36 | $-0.09 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | After market close | $205.70M | $-0.29 | $0.00 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $213.10M | $-3.57 | $0.05 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $196.00M | $0.00 | $-0.03 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 15, 2025 | Before market open | $209.00M | $-0.72 | $0.03 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $213.00M | $-0.24 | $0.06 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 16, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted Gross Margin %non-GAAP | full-year 2026 | 66% to 67% | Lowered |
| Revenue | full-year 2026 | $770.00M to $790.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Myriad Genetics filed with the SEC
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myriad Genetics Reports Second Quarter 2026 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports First Quarter 2026 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Third Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K/A
Myriad Genetics Reports Third Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Second Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Announces New $200 Million Credit Facility
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Myriad Genetics Reports First Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myriad Genetics Announces Senior Leadership Transition
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Third Quarter 2024 Financial Result s; Updates 2024 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Governance Enhancements Exhibit Myriad Derivative Cases 18 K. Appointment of New Director. 1. The Company appointed Paul Bisaro to the Board in October 2022.
Regulation FD disclosure · EX-99.2 to Form 8-K
Three months ended December 31,
Results of operations · EX-99.1 to Form 8-K
©2024 Myriad Genetics, Inc. 42nd Annual J.P. Morgan Healthcare Conference J A N U A R Y 1 0 , 2 0 2 4 ©2024 Myriad Genetics, Inc.
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth ; Raises 20 23 Revenue Guidance and
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
Results of operations · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Myriad Genetics Reports Third Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Myriad Genetics Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Fourth Quarter 2021 Results,
Results of operations · EX-99.1 to Form 8-K
Myriad Genetics Reports Third Quarter 2021 Results,
Results of operations · EX-99.1 to Form 8-K